Rokote Laboratories Finland Oy
We are a Finnish vaccine development company.
Our company was established in 2020, when the development of our first vaccine was also started. Our premises are located in Kuopio and Helsinki.
Our company’s operations were founded on research cooperation based on the competence of the University of Helsinki and the University of Eastern Finland. In 2021, our company received EUR 9 million in funding (Ferring Ventures SA, Jenny and Antti Wihuri Fund, Finnish Cultural Fund, and Business Finland) for the development, manufacture, and implementation of our FINCoVac coronavirus vaccine, as well as for the first and second phases of clinical trials.
Our company was established in 2020, when the development of our first vaccine was also started. Our premises are located in Kuopio and Helsinki.
Our company’s operations were founded on research cooperation based on the competence of the University of Helsinki and the University of Eastern Finland. In 2021, our company received EUR 9 million in funding (Ferring Ventures SA, Jenny and Antti Wihuri Fund, Finnish Cultural Fund, and Business Finland) for the development, manufacture, and implementation of our FINCoVac coronavirus vaccine, as well as for the first and second phases of clinical trials.
We are developing the Finnish COVID-19 vaccine
The development is based on the knowledge and cooperation of Professor Kalle Saksela, Academic Kari Alitalo, and Academy Professor Seppo Ylä-Herttuala. It has been possible to rapidly promote the development of our vaccine, as it is based on a knowledge base created through long-term research.
Our FINCoVac vaccine is administered into the nose, because the coronavirus naturally causes infection via the airways. A vaccine administered onto the nasal mucosa is expected to give a wider immune response than a vaccine administered into the muscle.
Our FINCoVac vaccine is administered into the nose, because the coronavirus naturally causes infection via the airways. A vaccine administered onto the nasal mucosa is expected to give a wider immune response than a vaccine administered into the muscle.
.
.
Clinical trials
Our goal is to start the first clinical trial with the FINCoVac 2.1 vaccine in Finland during the year 2023. At that time, adult volunteers who are already fully vaccinated with other coronavirus vaccine(s) will be invited to participate in the clinical trial.
For legal reasons, recruitment of volunteer subjects may only begin once we have been granted trial authorisation from the authorities. Unfortunately, we are unable to receive volunteer enrolments in advance. We will provide more information about our clinical trials and their participation closer to the start of the trials.
For legal reasons, recruitment of volunteer subjects may only begin once we have been granted trial authorisation from the authorities. Unfortunately, we are unable to receive volunteer enrolments in advance. We will provide more information about our clinical trials and their participation closer to the start of the trials.
Building a safer future
The mutation of the SARS-CoV-2 virus to evade the immune system is likely to continue at a rapid pace and new variant outbreaks may be expected. As the protection produced by the vaccines deteriorates over time, a booster and protection against variants of the coronavirus is required. Our vaccines are being developed to meet the challenges that the variants pose. Our cooperation with other companies and stakeholders provides a fruitful basis for new ideas, for the social impact of research, and for solutions to crises in society (such as the COVID-19 pandemic).
Our aim is to build and secure Finnish and European security of supply and vaccine self-sufficiency with our vaccine and to contribute to the global challenge of the coronavirus pandemic.
Our aim is to build and secure Finnish and European security of supply and vaccine self-sufficiency with our vaccine and to contribute to the global challenge of the coronavirus pandemic.